Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-20093 or SHR2554 in Metastatic Prostate Cancer
NCT07230106Phase 2Recruiting
- Sponsor
- Hengrui
- Start
- Dec 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules, Antibody-Drug Conjugates (ADCs)
- Countries
- 1
01
Overview
A Phase 2 trial of risvutatug rezetecan, zeprumetostat in prostate cancer (PCa), sponsored by Hengrui. Started Dec 2025; status: recruiting.
02
Drugs
risvutatug rezetecanzeprumetostat
03
Conditions
prostate cancer (PCa)
Beyond the preview
Go deeper on NCT07230106.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07230106.